SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis.

SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis.
复制标题

新冠肺炎危机中的SARS-CoV-2疫苗和自身免疫性疾病

DOI:
10.1007/s00296-021-04792-9
复制
发表时间:
2021-03
影响因子:
4
通讯作者:
Georgiev T
Georgiev T
中科院分区:
医学3区
文献类型:
--
作者:
Velikova T;Georgiev T

文献摘要

参考文献

被引文献

相似文献

即使对于最持久的医疗保健系统来说,2019 年冠状病毒病(COVID-19)大流行也变得充满挑战。疫苗接种作为最有效的公共卫生干预措施之一,似乎为通过实现群体免疫来结束大流行带来了一线希望。在这篇综述中,我们的目的是针对自身免疫性炎症性疾病 (AIID) 涵盖严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 疫苗和候选疫苗的当前知识,并分析它们在 AIID 患者中的安全性和有效性方面的潜力。因此,进行了重点叙述性综述,以预测不同类型 SARS-CoV-2 疫苗可能产生的影响,这些疫苗赋予不同的免疫机制来建立免疫反应并针对 COVID-19 提供保护:整个病毒(灭活或减弱)、病毒载体(复制和非复制)、核酸(RNA、DNA)和基于蛋白质的(蛋白质亚基、病毒样颗粒)。尽管如此,AIID 患者和临床医生对新疫苗的有效性和安全性仍存在不确定性。有多种方法可以建立针对 SARS-CoV-2 的保护性免疫力。只有高质量的临床试验才能阐明新使用的疫苗/佐剂对 AIID 患者的潜在免疫机制。
Coronavirus disease 2019 (COVID-19) pandemic has become challenging even for the most durable healthcare systems. It seems that vaccination, one of the most effective public-health interventions, presents a ray of hope to end the pandemic by achieving herd immunity. In this review, we aimed to cover aspects of the current knowledge of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines and vaccine candidates in the light of autoimmune inflammatory diseases (AIIDs) and to analyze their potential in terms of safety and effectiveness in patients with AIIDs. Therefore, a focused narrative review was carried out to predict the possible implications of different types of SARS-CoV-2 vaccines which confer distinct immune mechanisms to establish immune response and protection against COVID-19: whole virus (inactivated or weakened), viral vector (replicating and non-replicating), nucleic acid (RNA, DNA), and protein-based (protein subunit, virus-like particle). Still, there is uncertainty among patients with AIIDs and clinicians about the effectiveness and safety of the new vaccines. There are a variety of approaches towards building a protective immunity against SARS-CoV-2. Only high-quality clinical trials would clarify the underlying immunological mechanisms of the newly implemented vaccines/adjuvants in patients living with AIIDs.
DOI: 10.1038/nrrheum.2009.196
发表时间: 2009-11-01
影响因子: 33.7
作者:
Agmon-Levin, Nancy;Paz, Ziv;Shoenfeld, Yehuda
通讯作者: Shoenfeld, Yehuda
DOI: 10.1016/s0140-6736(20)32642-8
发表时间: 2021-01-02
期刊: Lancet (London, England)
影响因子: --
作者:
Burgess RA;Osborne RH;Yongabi KA;Greenhalgh T;Gurdasani D;Kang G;Falade AG;Odone A;Busse R;Martin-Moreno JM;Reicher S;McKee M
通讯作者: McKee M
DOI: 10.1006/jaut.2000.0491
发表时间: 2001-05-01
影响因子: 12.8
作者:
Chen, RT;Pless, R;DeStefano, F
通讯作者: DeStefano, F
DOI: 10.1038/s41562-020-01009-0
发表时间: 2020-11-16
影响因子: 29.9
作者:
Haug, Nils;Geyrhofer, Lukas;Klimek, Peter
通讯作者: Klimek, Peter
DOI: 10.1038/srep37817
发表时间: 2016-12-02
期刊: Scientific reports
影响因子: 4.6
作者:
Chang CC;Chang YS;Chen WS;Chen YH;Chen JH
通讯作者: Chen JH